ΝΟΣΟΚΟΜΕΙΑΚΑ ΧΡΟΝΙΚΑ

56Η εποχή της Φαρμακογενωμικήςphisms of the CYP3A4, CYP3A5 and MDR−1 genesand pharmacokinetics of the calcineurin inhibi−tors cyclosporine and tacrolimus. Clin Pharma−col Ther 2003; 74:245−54. b) Α Γρηγοράτου, ΑΜελπίδου. Κυκλοσπορίνη: Οδοιπορικό στηνανοσοκαταστολή. Ενημερωτικό Δελτίο ΕλληνικήςΕταιρίας Κλινικής Χημείας – Κλινικής Βιοχημείας.Τεύχος 47, 2008.30. Y Dai, MF Herbert, N Ischerrannen, CL Davis etal. Effect of CYP3A5 polymorphisms on tacrolimusmetabolic clearance in vitro. Drug Metab Dispos2006; 836−847.31. W Steimer, K Zopf, S von Amelunxen, H Pfeifferet al. Amitriptyline or not, that is the question:pharmacogenetic testing of CYP2D6 and CYP2C9identifies patients with low or high risk for sideeffects in amitriptyline therapy. Clin Chem 2005;51:376−385.32. Jde Leon, MT Susce, RM Pan, M Faichild, WH Koch,PJ Wedlund. The CYP2D6 poor metabolizer pheno−type may be associated wi thrisperidone adversedrug reactionsand discontinuation. J Clin Psychiatry2005; 66:15−27.33. JBrockmoller, J Kirchheiner, J Schmider, S Walter etal. The impact of CYP2D6 polymorphism on halo−peridol pharmaco−kinetics and on the outcome ofhaloperidol treatment. Clin Pharmacol Ther 2002;72:438−452.34. YW Law, A Gaedigk, L Ereshfskyl, CL Alfaro, J Simp−son. CYP inhibition by SSRI. Pharmacother 2002; 22:1001−1006.35. K Laine, G Tybring, S Hartter, K Andersson et al.Inhibition of CYPD6 activity with paroxetine nor−malises the ultrarapid metabolizer phenotype asmeasured with nortriptyline pharmaco−kinetics andthe debrisoquin test. Clin Pharmacol Ther 2001;70:327−335.36. J Kirchheimer, C Heesch, S Bauer, C Mersec etal. Impact of ultrarapid metabolizer phenotype onmetoprolol pharmacokinetics and pharmacody−namics. Clin Pharmacol Ther 2004; 76:302−312.37. FJ Gonzales, P Fernadez−Salguero. Diagnostic anal−ysis, clinical importance and molecular basis of de−hydrogenase deficiency. TIPS 1995; 16:325−327.38. RF Frye. Probing the world of CYP450 enzymes.Mol Interv 4; 157−162.39. MG Scordo, V Pengo, E Spina, MC Dahl, M Gu−selle, K Perdini. Influence of CYP2C9 and CYP2C19genetic polymorphisms on warfarin maintenancedose and metabolic clearance. Clin Pharmacol Ther2002; 72:702−710.40. EA Sconce, TI Khan, HA Wynne, P Avery et al. Theimpact of CYP2C9 and VKORC1 genetic polymor−phisms and patients characteristics upon warfarindose requirements: proposal for a new dosing regi−ment. Blood 2005; 2329−2333.41. MJ Rieder, AP Reiner, BF Gage, DA Nickerson etal. Effect of VKORC1 halpotypes on transcriptionalregulation and warfarin dose. N Engl J Med 2005;352:2285−2293.42. L Fu, BYL Wong, DEC Cole. The impact of geneticvariations on warfarin dose requirements. Asian–Pacific Clin Chem Conf. Oct 2007. Chinese MedJ 2007; 1205−1209.43. CR Lee, JA Deeper, RF Frye, AL Hinderliter et al.Tolbutamide, flurbiprofen and losartan as probes ofCYP2C9 activity in humans. J Clin Pharmacol 2003;43:84−91.44. U Klotz, M Schuab, G Treiber. CYP2C19 polymor−phisms and PPI inhibitors. Basic. Clin PharmacolToxicol 2004; 95:2−8.45. T Furuta, N Shirai, M Sugimoto, K Ohoshi, T Ishizaki.Pharmacogenetics of PPI. Pharmacogenomics 2004;5:181−202.46. CC Hung, CJ Lin, CJ Chang, HH Liou. Dosage rec−ommendation of phenytoin for patients with epi−lepsy with different CYP2C9 and CYP2C19 poly−morphisms. Ther Drug Monit 2004; 26:534−540.47. Q Ma, D Brazeau, A Forrest, D Morse. Advancesin pharmacogenomics of antiretrovirals: an update.Pharmaco−genomics 2007; 8:1169−1178.48. S Rodriguez−Novoa, L Martin−Carbonero, P Bar−reiro, et al. Genetic factors influencing atazanavirplasma concentra−tions and the risk of severe hy−perbili−rubinaemia. AIDS 2007; 21:41−46.49. A Saitoh, CV Fletcher, K Brundage et al. Efavirezpharmacokinetics in HIV−1 infected children areassociated with CYPB6−G5T16 polymorphism. J Ac−quir Immun Defic Syndr 2007; 45:41−46.50. J Fox, Boffito, A Winston. The clinical implicationsof antiretroviral pharmacoge−nomics. Pharmacoge−nomics 2006; 7:587−596.51. ΜΕ van der Akker−van Marie, D Gurwitz, SB Det−mar, CM Enzing et al. Cost−effectiveness of phar−macogenomics in clinical practice: a case study ofthiopurine methyltransferase genotyping in acutelymphoblastic leukemia in Europe. Pharmacoge−nomics 2006; 7:783−792.